ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2602

Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus

Caseng Zhang1, Nicholas Gold2, Raffaella Carlomagno3, JingJing Cao4, Daniela Dominguez4, Dafna Gladman5, Mariko Ishimori6, Caroline Jefferies7, Diane Kamen8, Sylvia Kamphuis9, Marisa Klein-Gitelman10, Andrea Knight11, Chia-Chi Lee12, Deborah Levy2, Lawrence Ng2, Karen Onel13, Andrew Paterson4, Christine Peschken14, Janet Pope15, Earl Silverman16, Zahi Touma17, Murray Urowitz18, Daniel Wallace19, Joan Wither20 and Linda Hiraki2, 1University of Ottawa, Ottawa, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3Lausanne University Hospital, Toronto, ON, Canada, 4The Hospital for Sick Children, Toronto, Canada, 5University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 6Cedars-Sinai Health System, Los Angeles, CA, 7Cedars-Sinai Medical Center, Beverly Hills, CA, 8Medical University of South Carolina, Charleston, SC, 9Erasmus University Medical Center, Rotterdam, Netherlands, 10Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 11Division of Rheumatology, The Hospital for Sick Children; Neurosciences and Mental Health, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, 12Cedars-Sinai Medical Center, Los Angeles, CA, 13HSS, New York, NY, 14University of Manitoba, Winnipeg, MB, Canada, 15University of Western Ontario, London, ON, Canada, 16Silverman, Toronto, ON, Canada, 17University of Toronto, Toronto, ON, Canada, 18Self employed, Toronto, ON, Canada, 19Cedars Sinai Medical Center, Studio City, CA, 20University Health Network, Toronto, ON, Canada

Meeting: ACR Convergence 2024

Keywords: genetics, Genome Wide Association Studies, Pediatric rheumatology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: SLE – Etiology & Pathogenesis

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease with multi-organ involvement and a strong female predominance. Prior studies demonstrated sex dimorphism in SLE manifestations, with female SLE patients more commonly having malar rash and arthritis, and male SLE patients with a higher prevalence of renal disease. Genetics play a role in SLE risk, but few studies have tested sex chromosome loci for differences in disease manifestations. This study aimed to identify X chromosome loci for SLE sub-phenotypes in a multi-ethnic cohort of children and adults with SLE.

Methods: Our study included patients with childhood-onset (cSLE) and adult-onset (aSLE) from 9 tertiary care centers in North America and Europe who met American College of Rheumatology (ACR) or Systemic Lupus International Collaborating Clinics (SLICC) SLE classification criteria and were genotyped on a multi-ethnic array. Ungenotyped SNPs were imputed using TopMed as a referent. Principal Components (PCs) were generated to account for ancestral variation. Phenotypic variables derived from SLE classification criteria were tested for sex dimorphism in the entire cohort and age stratified groups, with significance set at P < 0.05. An X chromosome analysis was performed for significant SLE phenotypes, controlling for sex and 5 PCs. X-wide significance was set at P < 5 × 10-8.

Results: Our study included 1553 participants and 88% were female. A total of 819 (53%) were cSLE patients with a median age at diagnosis of 14.1 years (IQR: 11.8 – 15.9), while the median age at diagnosis for aSLE patients was 31.2 years (IQR: 24.8 – 42.4). Among females there was a higher prevalence of arthritis, mucocutaneous features, and hematologic features, while lupus nephritis and anti-Smith, anti-Ro, and anti-RNP antibodies were more prevalent among males. [Table 1.] Chromosome X analyses identified significant loci for hematologic features (rs2768083, OR = 1.92, 95%CI: 1.64 – 2.24; P = 1.39 × 10-16 and rs139494182, OR = 0.57, 95%CI: 0.47 – 0.69; P = 1.18 × 10-8), mucocutaneous features (rs1751732, OR = 1.82, 95%CI: 1.53 – 2.15; P = 8.27 × 10-12), and Ro antibody (rs5939599, OR = 1.69, 95%CI: 1.41 – 2.03; P = 1.83 × 10-8 and rs34494682, OR = 0.49, 95%CI: 0.38 – 0.63; P = 3.62 × 10-8). [Figure 1.] Three SNPs on the long arm of Chromosome X associated with hematologic abnormalities, mucocutaneous features, and anti-Ro antibody positivity appear to be in varying degrees of linkage disequilibrium (D’ > 0.9, R2 between 0.3 and 0.7).

Conclusion: Our multi-ancestral study of children and adults with SLE identified X chromosome SNPs associated with sex dimorphic SLE features: hematologic abnormalities, mucocutaneous features, and anti-Ro antibody positivity. To further investigate genetics of sexual dimorphism in SLE manifestations, we will complete stratified analyses by ancestry as well as studies into whether any of these loci are expression quantitative trait loci.

Supporting image 1

Table 1. Demographic characteristics of SLE cohort

Supporting image 2

Figure 1. Manhattan plot of X Chromosome against hematologic features (A), mucocutaneous features (B), and positive Ro antibody (C)†


Disclosures: C. Zhang: None; N. Gold: None; R. Carlomagno: None; J. Cao: None; D. Dominguez: None; D. Gladman: AbbVie, 2, 5, Amgen, 2, 5, AstraZeneca, 2, BMS, 2, Celgene, 2, 5, Eli Lilly, 2, 5, Galapagos, 2, 5, Gilead, 2, 5, Janssen, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, UCB, 2, 5; M. Ishimori: None; C. Jefferies: Amgen, 11, Eli Lilly, 5, 11, Takeda, 3; D. Kamen: Alpine Immune Sciences, 1, Bristol Myers Squibb (BMS), 1; S. Kamphuis: None; M. Klein-Gitelman: AbbVie/Abbott, 2, AstraZeneca, 2, Eli Lilly, 1; A. Knight: Pfizer, 6; C. Lee: None; D. Levy: AbbVie, 5, AstraZeneca, 5, Roche, 5, SOBI, 5; L. Ng: None; K. Onel: None; A. Paterson: None; C. Peschken: AstraZeneca, 1, GlaxoSmithKlein(GSK), 1, Roche, 1; J. Pope: None; E. Silverman: None; Z. Touma: None; M. Urowitz: None; D. Wallace: None; J. Wither: AstraZeneca, 1, 2, Pfizer, 5; L. Hiraki: Janssen, 2.

To cite this abstract in AMA style:

Zhang C, Gold N, Carlomagno R, Cao J, Dominguez D, Gladman D, Ishimori M, Jefferies C, Kamen D, Kamphuis S, Klein-Gitelman M, Knight A, Lee C, Levy D, Ng L, Onel K, Paterson A, Peschken C, Pope J, Silverman E, Touma Z, Urowitz M, Wallace D, Wither J, Hiraki L. Genetics of Sex Dimorphism in Clinical Manifestations of Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/genetics-of-sex-dimorphism-in-clinical-manifestations-of-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genetics-of-sex-dimorphism-in-clinical-manifestations-of-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology